RhumbLine Advisers’s Audentes Therapeutics, Inc BOLD Stock Holding History

RhumbLine Advisers’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-65,035	Closed	-$3.89M	–	2963
2019 Q4	$3.89M	Buy	65,035 +3,984	+7%	+$150K	0.01%	1411
2019 Q3	$1.72M	Buy	61,051 +1,070	+2%	+$36.5K	﹤0.01%	1822
2019 Q2	$2.27M	Buy	59,981 +10,633	+22%	+$409K	﹤0.01%	1664
2019 Q1	$1.93M	Buy	49,348 +3,198	+7%	+$91.7K	﹤0.01%	1740
2018 Q4	$984K	Buy	46,150 +16,632	+56%	+$429K	﹤0.01%	2023
2018 Q3	$1.17M	Sell	29,518 -1,591	-5%	-$59.3K	﹤0.01%	1935
2018 Q2	$1.19M	Buy	31,109 +14,101	+83%	+$522K	﹤0.01%	1934
2018 Q1	$511K	Buy	17,008 +3,657	+27%	+$124K	﹤0.01%	2203
2017 Q4	$417K	Hold	13,351	–	–	﹤0.01%	2312
2017 Q3	$374K	Buy	13,351 +170	+1%	+$3.69K	﹤0.01%	2456
2017 Q2	$252K	Buy	+13,181	New	+$211K	﹤0.01%	2645

RhumbLine Advisers's BOLD Position: Q1 2020 in Review

RhumbLine Advisers sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 65,035 shares — an estimated $3.89M sold.

RhumbLine Advisers first reported a position in BOLD in Q2 2017 and held it in 11 quarters. The position peaked at $3.89M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

RhumbLine Advisers reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
RhumbLine Advisers sold 65,035 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $3.89M.
RhumbLine Advisers first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 11 quarters.
RhumbLine Advisers's Audentes Therapeutics, Inc position peaked at $3.89M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on RhumbLine Advisers's 13F filing for Q1 2020, filed 6 May 2020.